Drug intelligence / Profile preview

fecal microbiota transplant (Masonic Cancer Center)

Development stage: Unknown
Lead developer: University of Minnesota
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Cell Therapies, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Fecal microbiota transplant (FMT) is an investigational live biotherapeutic product being developed by the Masonic Cancer Center and the University of Minnesota. It is being evaluated in a randomized, double-blind, placebo-controlled Phase 2 clinical trial (NCT03692520) for the prevention of infections (bacterial, viral, and fungal) and graft-versus-host disease (GVHD). The trial enrolls patients with acute myeloid leukemia (AML) undergoing intensive chemotherapy and recipients of allogeneic hematopoietic cell transplantation (allo-HCT). [4] The therapy, administered as oral capsules, aims to restore a healthy gut microbiome that has been disrupted by antibiotics and chemotherapy, thereby potentially reducing infection rates and modulating the immune system to prevent GVHD. [3, 7] While the trial did not meet its primary endpoint of reducing overall infection rates, analysis suggests that donor microbiota engraftment may be associated with a lower rate of acute GVHD. [3, 4]

Other names: Fecal Microbiota Transplant (FMT)

Beyond the preview

Go deeper on fecal microbiota transplant (Masonic Cancer Center).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fecal microbiota transplant (Masonic Cancer Center).

Explore the full profile